Next Article in Journal
Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study
Next Article in Special Issue
Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
Previous Article in Journal
Liquid Crystal Nanoparticle Conjugates for Scavenging Reactive Oxygen Species in Live Cells
Previous Article in Special Issue
Revolutionization in Cancer Therapeutics via Targeting Major Immune Checkpoints PD-1, PD-L1 and CTLA-4
 
 
Article

Article Versions Notes

Pharmaceuticals 2022, 15(5), 605; https://doi.org/10.3390/ph15050605
Action Date Notes Link
article xml file uploaded 14 May 2022 12:18 CEST Original file -
article xml uploaded. 14 May 2022 12:18 CEST Update https://www.mdpi.com/1424-8247/15/5/605/xml
article pdf uploaded. 14 May 2022 12:18 CEST Version of Record https://www.mdpi.com/1424-8247/15/5/605/pdf
article supplementary file uploaded. 14 May 2022 12:18 CEST - https://www.mdpi.com/1424-8247/15/5/605#supplementary
article html file updated 14 May 2022 12:20 CEST Original file -
article html file updated 2 August 2022 23:54 CEST Update https://www.mdpi.com/1424-8247/15/5/605/html
Back to TopTop